As a result, our IFNGrGS had comparable performance to the IFNG gene signature and IFNG expand gene signature in predicting the GBM response to anti-PD1 and anti-CTLA4 therapies (Bonferroni corrected p < 0.05) (Figure 7), suggesting that the IFNGrGS based stratification has the potential to identify ICB responders. Here, CTLA4 is linked to glioblastoma.